Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Voltage-gated sodium channels (VGSCs) are increasingly implicated in driving cancer cell invasiveness.
• Hypoxia, common in tumors, promotes a persistent sodium current (I_NaP) via VGSCs.
• Ranolazine selectively blocks this I_NaP current.

Purpose of the Study:

• To investigate the anti-metastatic potential of ranolazine in various cancer types.
• To evaluate the efficacy of ranolazine in preclinical models and patient data.
• To assess ranolazine's impact on chemotherapy side effects.

Main Methods:

• In vitro assays examining cancer cell invasiveness under hypoxic conditions.
• In vivo studies assessing metastasis in breast cancer, prostate cancer, and melanoma models.
• Retrospective epidemiological analysis of survival data from breast, colon, and prostate cancer patients.

Main Results:

• Ranolazine significantly inhibited cancer cell invasiveness in vitro, especially under hypoxia.
• In vivo, ranolazine suppressed metastasis in multiple cancer types.
• Patient data revealed a ~60% reduction in cancer mortality risk for ranolazine users, with benefits observed even when initiated years post-diagnosis.
• Ranolazine also mitigated chemotherapy-induced cardiotoxicity and neurotoxicity.

Conclusions:

• Ranolazine demonstrates significant anti-metastatic properties and potential for reducing cancer mortality.
• It may serve as a safe alternative or adjunct to current systemic cancer therapies.
• Combination therapy with ranolazine could enhance anti-cancer effectiveness.